Cynata Therapeutics (ASX:CYP), a biotech company advancing stem cell therapies, needed a strategic communications partner to support with investor communication, media relations, and social media content and community management. One that understood how to navigate the complex landscape of ASX-listed biotech communications. The objective was to build and maintain visibility with investors, media, and stakeholders while managing the inherent sensitivities of clinical trial announcements and regulatory developments.
The approach
Little Big Deal was embedded into Cynata's operations as an outsourced communications adviser on a monthly retainer model. This included monthly investor correspondence (EDMs, statements, Q&A materials), proactive media outreach and newsjacking, ASX material development (releases, presentations, annual reports, quarterly reports), social media management, and strategic advice on emerging risks and issues. The approach ensured consistent, credible messaging across all stakeholder touchpoints while maintaining the rigor required for ASX compliance.
Impact and why it mattered
Over five years, the partnership established Cynata as a credible, communicative biotech player in a crowded field. Consistent, strategic media relations secured coverage across business and biotech publications. Investor communications maintained confidence through clinical trial milestones, regulatory developments, and capital raises. The longevity of the engagement – five years – reflects the trust built through reliable, expert counsel during high-stakes announcements and sensitive market periods.
“Communicating as a listed biotech company is difficult. It involves explaining complex science and product development programs to investors from diverse backgrounds, while ensuring that we adhere to strict ASX compliance requirements, sometimes under extreme time pressure. Lauren was an extension of our team, giving us calm, considered advice, and taking a hands-on approach to sharpen our messaging and build our profile. I wouldn't hesitate to recommend Little Big Deal to any ASX-listed company. ”
